Independent research on the U.S. markets, Baptista Research

Baptista Research

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. 

We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Stryker Corporation is moving deeper into the peripheral vascular market through its planned acquisition of Amplitude Vascular Systems for up to $835 million, adding a next-generation hydraulic intravascular lithotripsy platform designed to treat calcified peripheral arterial disease.</li><li>The deal comes at a notable moment for Stryker, which recently reported a disrupted Q1 2026 due to a cyber incident but maintained full-year guidance, citing healthy procedure volumes, strong capital demand, and confidence in sales recovery through the remainder of the year.</li><li>Management also described the AVS transaction as a step toward expanding treatment options for peripheral vascular customers and broadening Stryker’s presence in cardiovascular care.</li></ul>

Stryker Corporation is moving deeper into the peripheral vascular market through its planned acquisition of Amplitude Vascular Systems for up to $835 million, adding a next-generation hydraulic intravascular lithotripsy platform designed to treat calcified peripheral arterial disease.The deal comes at a notable moment for Stryker, which recently reported a disrupted Q1 2026 due to a cyber incident but maintained full-year guidance, citing healthy procedure volumes, strong capital demand, and confidence in sales recovery through the remainder of the year.Management also described the AVS transaction as a step toward expanding treatment options for peripheral vascular customers and broadening Stryker’s presence in cardiovascular care.

Stryker Takeover Play: The $835M Deal That Could Reshape Its Cardiovascular Future!